Welcome to our dedicated page for Gt Biopharma SEC filings (Ticker: GTBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the progress of GT Biopharma’s TriKE® cancer platform through SEC disclosures can feel like decoding lab notes. Each 10-K details complex immuno-oncology science, while 8-K reports announce pivotal Phase 1 updates the moment they reach EDGAR. If finding those nuggets inside hundreds of pages is challenging, you’re not alone.
Stock Titan’s AI engines turn every GT Biopharma SEC filing into plain-English insight. Need the latest GT Biopharma quarterly earnings report 10-Q filing without wading through accounting footnotes? Our summaries surface R&D burn rates and cash runway instantly. Wondering about GT Biopharma insider trading Form 4 transactions? Receive GT Biopharma Form 4 insider transactions real-time, complete with context on option grants and clinical milestone incentives. From the GT Biopharma annual report 10-K simplified to a GT Biopharma proxy statement executive compensation breakdown, every document is parsed, tagged and linked to the data investors ask for.
Here’s what you’ll find:
- AI-powered summaries that make understanding GT Biopharma SEC documents with AI straightforward.
- Automatic alerts when an GT Biopharma 8-K material events explained filing discloses trial results or new licensing deals.
- Side-by-side GT Biopharma earnings report filing analysis for quarter-over-quarter trend spotting.
- Direct links to GT Biopharma executive stock transactions Form 4 for pattern recognition before catalysts.
Whether you’re assessing dilution risk, monitoring NK-cell trial data, or comparing management’s stock moves to pipeline momentum, Stock Titan delivers all GTBP filings—updated in real time and explained simply—so you can focus on decisions, not document hunts.
GT Biopharma, Inc. (Nasdaq: GTBP) has filed Amendment No. 1 to its Form S-1 shelf registration statement dated 27 June 2025. The filing registers up to 54,423,826 shares of common stock for resale by several selling stockholders. GT Biopharma will not receive proceeds from the resale of these shares, though it could receive cash upon the initial issuance of certain securities (e.g., warrant exercises or sales under a committed equity facility).
Share-count breakdown
- 14,561,913 shares issuable on conversion of 6,612 shares of Series L 10% Convertible Preferred Stock issued in a May 2025 private placement.
- 14,561,913 shares issuable upon exercise of related common stock warrants.
- 300,000 commitment shares issuable on exercise of pre-funded warrants issued to Bristol Capital, LLC and Five Narrow Lane, L.P.
- Up to 25,000,000 shares issuable and resellable by the Facility Investors (Five Narrow Lane, L.P. and Hailstone Peak Funding, LLC) under a committed equity facility (CEF) established on 14 May 2025.
The company has agreed to bear registration expenses; selling stockholders will cover brokerage or underwriting costs. The registration gives stockholders the flexibility to dispose of shares “from time to time” using various methods outlined under “Plan of Distribution.”
Corporate and filing status
- State of incorporation: Delaware.
- Filer status: Non-accelerated filer & Smaller Reporting Company.
- GTBP became a fully remote company effective 1 July 2024 and lists a mailing address at 505 Montgomery St., San Francisco.
- Nasdaq Capital Market ticker: GTBP; closing price on 26 June 2025 was $3.80.
Key investor considerations
- The potential issuance of 54.4 million shares represents meaningful dilution relative to current outstanding shares and may exert downward pressure on the share price.
- While no resale proceeds flow to GTBP, the committed equity facility (up to 25 million shares) could provide future funding when shares are initially sold to the Facility Investors.
- The prospectus directs investors to the “Risk Factors” section (page 7) for a detailed discussion of material risks associated with the securities.
FAQ
What is the current stock price of Gt Biopharma (GTBP)?
What is the market cap of Gt Biopharma (GTBP)?
What is the core focus of GT Biopharma Inc?
How does GT Biopharma leverage its TriKE platform?
Which types of cancers does GT Biopharma target?
What differentiates GT Biopharma from other biopharmaceutical companies?
How does GT Biopharma approach clinical development?
What is the significance of the company’s focus on immuno-oncology?
How does GT Biopharma maintain its industry expertise and credibility?
